Prestige Consumer Healthcare Reports Q3 Results, Narrows FY26 Revenue & EPS Outlook
Summary
Prestige Consumer Healthcare Inc. reported third-quarter fiscal 2026 financial results, exceeding revenue outlook but narrowing its full-year fiscal 2026 revenue and adjusted diluted EPS guidance, primarily due to ongoing Clear Eyes® supply constraints.
Key Events
-
Q3 Revenue Exceeds Outlook
Reported Q3 FY26 revenue of $283.4 million, surpassing previous expectations, though down 2.4% year-over-year.
-
Full-Year Guidance Narrowed and Lowered
Fiscal 2026 revenue outlook narrowed to approximately $1.1 billion (from $1.1B-$1.115B) and adjusted diluted EPS to approximately $4.54 (from $4.54-$4.58), reflecting a slight downgrade at the high end.
-
Organic Revenue Growth Downgraded
Fiscal 2026 organic revenue growth outlook revised to an approximate 3.0% decrease, from a prior range of 1.5% to 3.0% decrease.
-
Clear Eyes® Supply Constraints Impact Sales
Revenue declines in Q3 and year-to-date were primarily driven by limited ability to supply demand for Clear Eyes®.
Analysis
Prestige Consumer Healthcare Inc. reported third-quarter fiscal 2026 financial results, exceeding revenue outlook but narrowing its full-year fiscal 2026 revenue and adjusted diluted EPS guidance, primarily due to ongoing Clear Eyes® supply constraints. The company's third-quarter performance showed revenue ahead of expectations, driven by a diversified portfolio. However, the year-over-year decline in revenue and EPS was largely attributed to persistent supply limitations for its Clear Eyes® product. While the acquisition of Pillar5 Pharma is expected to improve eye care supply, the updated fiscal 2026 outlook reflects a slight reduction in the high end of both revenue and adjusted diluted EPS guidance, alongside a more negative organic revenue growth projection. Investors will likely focus on the company's progress in resolving supply chain issues and the impact on future growth, despite strong free cash flow generation and continued share repurchases.
At the time of this filing, PBH was trading at $67.03 on NYSE in the Life Sciences sector, with a market capitalization of approximately $3.2B. The 52-week trading range was $57.25 to $90.04. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.